Six longevity trends, according to Andreessen Horowitz

Andreessen Horowitz says people are taking more control of their own health and spending money on it. The fund sees opportunities in health apps, “non-toxic” products, peptides, cholesterol drugs, smarter wearables and brain-sensing devices. Some of those markets rest on strong evidence and some do not.

Andreessen Horowitz (a16z), a major US venture capital firm, has published The State of Longevity, an analysis by two of its health investors, Daisy Wolf and Eva Steinman, based on a survey of 500 randomly selected US consumers and on trends the firm is following. Their central claim is that health-conscious behaviour that used to belong to biohackers has become mainstream. They attribute this to the COVID-19 pandemic, which exposed the limits of the medical system, and to AI chatbots, which made medical information easier to understand. The piece ends with a call for founders to get in touch. This is an investor’s view of a market the firm is investing in, which is worth remembering when reading it.

1. A single “healthcare home”

Today, the authors say, there is no single place to manage your health: records are scattered across doctors, portals, pharmacies and labs. A race is under way to build one app that holds your medical history, orders your tests, connects to your wearable, uses AI to explain results and links you to clinicians when you need treatment. They name Function Health, Oura, WHOOP, General Medicine, Counsel and Ferry Health, along with large technology companies, as contenders. Their argument is that as AI makes answers cheaper, the value will move to whoever handles the action, such as booking the test or arranging follow-up.

2. From organic to “non-toxic”

The survey found that 63 per cent of respondents knew about microplastics building up in the body and 35 per cent were concerned. In terms of behaviour, 70 per cent filter their water, 39 per cent have swapped plastic for glass, 37 per cent bought air purifiers, and 62 per cent said they would pay more for products labelled non-toxic. The authors acknowledge that spending is moving faster than evidence: people are paying for peace of mind even when the health benefit of a particular product is hard to measure.

3. Peptides beyond the GLP-1 drugs

GLP-1 drugs such as semaglutide and tirzepatide have transformed care for diabetes and obesity, and Eli Lilly’s tirzepatide brought in nearly $44 billion in the first nine months of 2026 alone. That success has fuelled consumer interest in other peptides that are not approved by the US Food and Drug Administration, such as BPC-157, promoted for tissue repair, and melanotan II, promoted for tanning. The authors state plainly that enthusiasm has outpaced evidence: strong human data on safety and efficacy are missing for many of these compounds, and buying from unregulated suppliers raises questions about what is in the vial. They expect investment to flow toward rigorously tested, regulated peptide drugs.

4. Cholesterol and heart health

The authors argue that heart disease prevention could become an everyday topic. They point to a study published in October in JAMA Cardiology, in which intensive treatment shrank plaque in the heart’s arteries by about a fifth over 18 months in people with heart disease. They also note that the first daily-pill PCSK9 inhibitor, a type of cholesterol-lowering drug previously available only as an injection, received FDA approval in July 2026; only 21 per cent of survey respondents had heard of the drug class.

Lipoprotein(a), an inherited risk factor that roughly one in five people has at high levels, is the next frontier. US guidelines now recommend testing it at least once in adulthood. The evidence for treating it is still incomplete: Novartis’s pelacarsen lowered Lp(a) but failed to reduce cardiovascular events in its main trial, while Lilly and Amgen drugs are still being tested.

5. Wearables, third generation

In the survey, 54 per cent of respondents use a wearable and 83 per cent of those check it daily, but 55 per cent say it has never prompted a behaviour change or a doctor’s visit. Nearly three in four would wear a second device if it measured something new. Companies the authors mention are developing a wearable that estimates hormone patterns without a blood draw and earrings that track blood flow, and Oura now flags patterns related to blood pressure. These are products in development or sold as wellness features, not validated medical measurements, and the authors tie their growth to a January 2026 FDA update of its general wellness policy, which lets some non-invasive devices offer wellness insights without medical-device clearance, as long as they stay within wellness claims.

6. Brain-computer interfaces and neurotech

Implanted devices such as Neuralink’s already let some trial participants with paralysis control computers, and a UCSF team has decoded speech from brain activity in people who cannot speak. Non-invasive headbands and caps are earlier-stage, and some aim to improve sleep and focus through stimulation. In the survey, 39 per cent said they would use a non-invasive brain-sensing device for sleep, focus or mood, and 29 per cent for thought-controlled devices, with more interest among men.

How to read the report

The survey is small, covers only the US, and measures willingness to pay and stated attitudes, not outcomes. Several of the trends, notably unregulated peptides and “non-toxic” products, are described by the authors themselves as running ahead of the evidence. The most robust section is the cardiovascular one, because it rests on published trials, although even there the benefit of Lp(a) drugs is unproven.

What it means for Central and Eastern Europe

None of the survey data comes from Europe, and the regulatory settings differ: the US wellness-device rules and the compounded peptide policies cited here do not apply in the EU, where medical-device, medicines and data-protection rules are stricter. The cardiovascular theme is the most transferable, because heart disease is a leading cause of death in the region, including in Hungary. Testing for Lp(a) once in adulthood is an existing recommendation in European lipid guidance, so a patient could ask a doctor about it today. For the rest, the realistic message for regional readers is caution: consumer interest in longevity is real, but products sold on its back vary widely in quality of evidence.


Disclaimer. This article is for general information only and is not investment, financial, legal or tax advice, or a recommendation to buy, sell or hold any security or product. Early-stage health and technology companies carry a high risk of loss, and forecasts and market opinions, including those of a venture investor with a financial interest in the sector, may prove wrong. Readers should do their own research and consult a suitably authorised financial adviser before making any investment decision. Nothing here is medical advice; consult a doctor before starting any treatment, supplement, peptide or test.

Transparency Note: This article was prepared with the assistance of artificial intelligence technologies. Every piece is thoroughly reviewed and verified by our editorial team, who retain full responsibility for the final content.

Picture: Freepik

Leave a Reply

Your email address will not be published. Required fields are marked *